Mrs Laura Alexander
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
Laura.Alexander@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
Publications
2023
Ferguson, J. et al. (2023) Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): Protocol of a prospective, multicentre, observational study. BMJ Open Respiratory Research, 10, e001771. (doi: 10.1136/bmjresp-2023-001771) (PMID:37996118) (PMCID:PMC10668291)
Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167) (PMCID:PMC10087532)
2021
Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)
Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)
Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)
2020
Tsim, S., Cowell, G. W. , Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)
Ferguson, J. et al. (2020) Staging by Thoracoscopy in Potentially Radically Treatable Non-Small Cell Lung Cancer Associated with Minimal Pleural Effusion (STRATIFY) study: a prospective multicentre study. Lung Cancer, 139(1), S92. (doi: 10.1016/S0169-5002(20)30245-2)
2019
Mileshkin, L. et al. (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 154(1), pp. 29-37. (doi: 10.1016/j.ygyno.2019.05.007) (PMID:31130288)
Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)
2018
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)
2017
Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)
Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)
2016
Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)
2011
Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)
Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)
Articles
Ferguson, J. et al. (2023) Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): Protocol of a prospective, multicentre, observational study. BMJ Open Respiratory Research, 10, e001771. (doi: 10.1136/bmjresp-2023-001771) (PMID:37996118) (PMCID:PMC10668291)
Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167) (PMCID:PMC10087532)
Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)
Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)
Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)
Tsim, S., Cowell, G. W. , Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)
Ferguson, J. et al. (2020) Staging by Thoracoscopy in Potentially Radically Treatable Non-Small Cell Lung Cancer Associated with Minimal Pleural Effusion (STRATIFY) study: a prospective multicentre study. Lung Cancer, 139(1), S92. (doi: 10.1016/S0169-5002(20)30245-2)
Mileshkin, L. et al. (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 154(1), pp. 29-37. (doi: 10.1016/j.ygyno.2019.05.007) (PMID:31130288)
Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)
Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)
Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)
Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)
Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)
Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)